Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $44000.0 for Q2 2023.

• Quarterly Receivables fell 98.01% year-over-year to $44000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $44000.0 (down 98.01% YoY) and the FY2022 annual result came in at $1.9 million, down 60.01% from the prior year.
• Receivables was $44000.0 for Q2 2023 at Avalo Therapeutics, down from $605000.0 in the prior quarter.
• Across five years, Receivables topped out at $5.6 million in Q1 2019 and bottomed at -$2.5 million in Q2 2019.
• A 5-year average of $2.2 million and a median of $2.2 million in 2022 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 4153.55% in 2019, while the deepest fall reached 2198.36% in 2019.
• Avalo Therapeutics' Receivables stood at $1.1 million in 2019, then slumped by 91.25% to $100000.0 in 2020, then soared by 2222.0% to $2.3 million in 2021, then tumbled by 73.94% to $605000.0 in 2022, then slumped by 92.73% to $44000.0 in 2023.
• Business Quant data shows AVTX's Receivables at $44000.0 in Q2 2023, $605000.0 in Q4 2022, and $2.1 million in Q3 2022.